PROSPECTUS SUPPLEMENT
(To Prospectus dated January 2, 2018)
![LOGO](https://capedge.com/proxy/424B5/0001193125-18-216266/g855394g53s99.jpg)
9,750,000 Shares
Common Stock
The forward sellers referred to below are offering 9,750,000 shares of our common stock, no par value. We expect to enter into forward sale agreements with an affiliate of Citigroup Global Markets Inc. and an affiliate of J.P. Morgan Securities LLC, which affiliates we refer to in such capacity as the “forward purchasers,” with respect to 9,750,000 shares of our common stock. In connection with these forward sale agreements, the forward purchasers or their respective affiliates, whom we refer to in such capacity as the “forward sellers,” at our request, are borrowing from third parties and selling to the underwriters an aggregate of 9,750,000 shares of our common stock. If the forward purchasers determine in good faith, after using commercially reasonable efforts, that the forward sellers are unable to borrow and deliver for sale on the anticipated closing date such number of shares of our common stock or that the forward sellers are unable to borrow, at a stock loan rate not greater than a specified rate, and deliver for sale on the anticipated closing date such number of shares of our common stock, or if the forward sellers elect not to borrow shares of our common stock because certain conditions in the underwriting agreement for this offering are not satisfied, then we will issue and sell to the underwriters a number of shares equal to the number of shares that the forward sellers do not borrow and sell.
We will not initially receive any proceeds from the sale of our common stock sold by the forward sellers to the underwriters, except in certain circumstances described in this prospectus supplement. We expect to fully physically settle the forward sale agreements and receive proceeds, subject to certain adjustments, from the sale of those shares of common stock in one or more settlements on or prior to December 15, 2019, which is the scheduled final settlement date under the forward sale agreements. If we elect to cash settle all or a portion of the forward sale agreements, we may not receive any proceeds from such election, and we may owe cash to the forward purchasers. If we elect to net share settle all or a portion of the forward sale agreements, we will not receive any cash proceeds from such election, and we may owe shares of our common stock to the forward purchasers. See “Underwriting (Conflicts of Interest) – Forward Sale Agreements.”
Concurrently with this offering, we are offering (the “Concurrent Offering”) 5,000,000 shares of our 6.75% Mandatory Convertible Preferred Stock, Series B, which offering is being made by means of a separate prospectus supplement and not by means of this prospectus supplement. The completion of this offering is not contingent on completion of the Concurrent Offering, and the completion of the Concurrent Offering is not contingent on the completion of this offering.
We intend to use the net proceeds we receive from the sale of shares of our common stock pursuant to the forward sale agreements and, if completed, from the sale of our 6.75% Mandatory Convertible Preferred Stock, Series B, in the Concurrent Offering to repay outstanding commercial paper, to fund working capital and for other general corporate purposes. See “Summary Information” and “Use of Proceeds.”
Our common stock is listed on the New York Stock Exchange under the symbol “SRE.” On July 10, 2018, the last reported sale price of our common stock on the New York Stock Exchange was $117.30 per share. On June 20, 2018, our board of directors declared a dividend of $0.8950 per share of our common stock payable on July 15, 2018 to shareholders of record as of the close of business on July 2, 2018.Purchasers of shares of our common stock in this offering will not be entitled to receive the dividend payable on July 15, 2018 on the shares of common stock that they purchase in this offering.
Investing in the shares involves risks. See the “Risk Factors” section on page S-19 of this prospectus supplement.
| | | | | | | | |
| | Per Share | | | Total | |
Public Offering Price | | $ | 113.750000 | | | $ | 1,109,062,500.00 | |
Underwriting Discount | | $ | 1.876875 | | | $ | 18,299,531.25 | |
Proceeds to Sempra Energy (1) | | $ | 111.873125 | | | $ | 1,090,762,968.75 | |
(1) | We expect to receive net proceeds from the sale of our common stock of $1,090,762,968.75 upon full physical settlement of the forward sale agreements, which we expect will occur in one or more settlements on or prior to December 15, 2019. For the purpose of calculating the net proceeds to us, we have assumed the forward sale agreements will be fully physically settled at the initial forward sale price of $111.873125 per share, which is equal to the public offering price per share less the underwriting discount shown above. The forward sale price is subject to adjustment pursuant to the forward sale agreements, and the actual proceeds, if any, will be calculated as described in this prospectus supplement. If the overnight bank funding rate decreases substantially prior to the settlement of the forward sale agreements, we may receive less than the initial forward sale price per share upon full physical settlement of the forward sale agreements. Although we expect to settle the forward sale agreements entirely by the full physical delivery of shares of our common stock in exchange for cash proceeds, we may elect cash settlement or net share settlement for all or a portion of our obligations under the forward sale agreements, in which case we may receive no cash proceeds or substantially less cash proceeds than is reflected in the above table upon settlement, or we may be required to deliver cash or shares of our common stock to the forward purchasers. See “Underwriting (Conflicts of Interest) – Forward Sale Agreements” for additional information. |
We have granted the underwriters the option, exercisable in whole or from time to time in part, to purchase up to an additional 1,462,500 shares of our common stock directly from us solely to cover over-allotments, if any, at the public offering price per share shown above, less the underwriting discount and subject to possible adjustment as described under “Underwriting (Conflicts of Interest),” exercisable for 30 days after the date of this prospectus supplement.
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares of common stock to purchasers on or about July 13, 2018.
Joint Book-Running Managers
| | | | |
Citigroup | | | | J.P. Morgan |
BofA Merrill Lynch | | Credit Suisse | | Deutsche Bank Securities |
Goldman Sachs & Co. LLC | | Wells Fargo Securities |
SeniorCo-Managers
| | | | |
BNP PARIBAS | | Credit Agricole CIB | | Mizuho Securities |
MUFG | | | | UBS Investment Bank |
July 10, 2018